Global Custom Market Research Reports Provider Company

phone

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017

  • Published Date: 03 Jul 2017
  • Number of Pages: 89
  • Category: Healthcare and Medical
  • Country: Global
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017

Summary

GlobalDatas "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in Q1 2017 with 1,142 deals worth USD95.5 billion, as compared 1,165 worth USD91.4 billion in Q1 2016. On a quarter-on-quarter basis, the number of deals and deal values increased in Q1 2017, when compared to 1,082 deals worth USD84.3 billion in Q4 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD731m in Q1 2017, as compared USD1.3 billion in Q1 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q1 2017, when compared to USD1 billion in Q4 2016. Deals in oncology therapeutics market registered an increase with 421 deals in Q1 2017, compared to 356 deals in Q4 2016.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and womens health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Publisher Name : GlobalData

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2017 10
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2017 10
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2017 12
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2017 13
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14
2.4.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 14
2.4.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 15
2.4.3 Pfizer Raises USD4.2 Billion in Public Offering of Notes 15
2.4.4 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 16
2.4.5 Fresenius Raises USD2.7 Billion in Private Placement of Notes 16
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2017 17
3.1.1 Top M&A Deals in Q1 2017 18
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2016 - Q1 2017 19
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2017 20
3.2.1 Top Initial Public Offerings in Q1 2017 21
3.2.2 Top Secondary Offerings in Q1 2017 21
3.2.3 Top PIPE Deals in Q1 2017 22
3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2016 - Q1 2017 23
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2017 24
3.3.1 Top Venture Financing Deals in Q1 2017 25
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017 26
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017 26
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2016 - Q1 2017 28
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2016 - Q1 2017 29
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016 - Q1 2017 30
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2017 31
3.4.1 Top Private Equity Deals in Q1 2017 32
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2016 - Q1 2017 33
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017 34
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017 34
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2016 - Q1 2017 35
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2017 36
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2017 37
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017 37
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2017 38
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 39
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2016 - Q1 2017 40
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2016 - Q1 2017 41
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 42
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2017 44
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2017 44
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 45
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2017 46
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2017 46
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2017 47
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2016 - Q1 2017 48
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2016 - Q1 2017 49
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2016 - Q1 2017 50
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2016 - Q1 2017 51
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2016 - Q1 2017 52
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2017 54
6.1.1 Oncology - Deals of the Quarter 55
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2017 56
6.2.1 Central Nervous System - Deals of the Quarter 57
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2017 59
6.3.1 Infectious Disease - Deals of the Quarter 60
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2017 61
6.4.1 Immunology - Deals of the Quarter 62
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2017 63
6.5.1 Metabolic Disorders - Deals of the Quarter 64
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2017 65
6.6.1 Cardiovascular - Deals of the Quarter 66
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2017 67
6.7.1 Gastrointestinal - Deals of the Quarter 68
6.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2017 70
6.8.1 Ophthalmology - Deals of the Quarter 71
6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2017 72
6.9.1 Respiratory - Deals of the Quarter 73
6.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2017 74
6.10.1 Dermatology - Deals of the Quarter 75
7 Deal Summary by Geography 77
7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2017 77
7.1.1 North America - Deals of the Quarter 78
7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2017 79
7.2.1 Europe - Deals of the Quarter 80
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2017 81
7.3.1 Asia-Pacific - Deals of the Quarter 82
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2017 83
7.4.1 Rest of the World - Deals of the Quarter 84
8 Pharmaceuticals & Healthcare, Global, Top Advisors 85
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2016 - Q1 2017 85
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2016 - Q1 2017 86
9 Further Information 87
9.1 Methodology 87
9.2 About GlobalData 88
9.3 Contact Us 88
9.4 Disclosure information 88
9.5 Disclaimer 89

List Of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 11
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2017 13
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 17
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2017 18
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2016 - Q1 2017 19
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 21
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2017 21
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2017 21
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2017 22
Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 23
Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 24
Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2017 25
Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2017 27
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 28
Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 29
Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016 - Q1 2017 30
Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 31
Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2017 32
Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 33
Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 34
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 35
Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 36
Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2017 37
Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017 37
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2017 38
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 39
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 41
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 43
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 44
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 45
Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2017 46
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2017 46
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2017 47
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 48
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2016 - Q1 2017 49
Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 51
Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 53
Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 55
Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 57
Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 60
Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 62
Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 64
Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 66
Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 68
Table 46: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 71
Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 73
Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 75
Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 78
Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 80
Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 82
Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 84
Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 85
Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 86

List Of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2017 12
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2017 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2016 - Q1 2017 17
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2016 - Q1 2017 19
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 20
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2016 - Q1 2017 23
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 24
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2017 26
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2017 26
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017 28
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 29
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 31
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2016 - Q1 2017 33
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 34
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 35
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 36
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 39
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 40
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016 - Q1 2017 41
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2016 - Q1 2017 42
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 44
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 45
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 48
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 49
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2016 - Q1 2017 50
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2016 - Q1 2017 51
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2016 - Q1 2017 52
Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 54
Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 56
Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 59
Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 61
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 63
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 65
Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 67
Figure 36: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 70
Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 72
Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 74
Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 77
Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 79
Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 81
Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 83
Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 85
Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2016 - Q1 2017 86

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2017 in Pharmaceuticals GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends for June 2017 in Pharmaceuticals , report is an essential

View Report

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals , report is an essential

View Report

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017 GlobalDatas Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2017 , report is an essential

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports